Effect of NCB-02, Atorvastatin and Placebo on Endothelial Function, Oxidative Stress and Inflammatory Markers in Patients with Type 2 Diabetes Mellitus: A Randomized, Parallel-Group, Placebo-Controlled, 8-Week Study

By Usharani P.  

Drugs in R&D, Vol. 9, Iss. 4, 2008-01 ,pp. : 243-250

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Atorvastatin in Patients with Type 2 Diabetes Mellitus: A Pharmacoeconomic Analysis of the Collaborative Atorvastatin Diabetes Study in the Belgian Population

By Annemans L.   Marbaix S.  

Clinical Drug Investigation, Vol. 30, Iss. 2, 2010-02 ,pp. : 133-142

Adis International

Access to resources Recommend Favorite

Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 15, Iss. 3, 2015-01 ,pp. : 223-228

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of the Effects of Policosanol and Atorvastatin on Lipid Profile and Platelet Aggregation in Patients with Dyslipidaemia and Type 2 Diabetes Mellitus

By Castaño G.  

Clinical Drug Investigation, Vol. 23, Iss. 10, 2003-01 ,pp. : 639-650

Adis International

Access to resources Recommend Favorite

Atorvastatin: A Review of its Use in the Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

By Croom Katherine F.   Plosker Greg L.  

Drugs, Vol. 65, Iss. 1, 2005-01 ,pp. : 137-152

Adis International

Access to resources Recommend Favorite